BR112019003408A2 - anticorpo monoclonal contra a melk e utilização da mesma - Google Patents
anticorpo monoclonal contra a melk e utilização da mesmaInfo
- Publication number
- BR112019003408A2 BR112019003408A2 BR112019003408A BR112019003408A BR112019003408A2 BR 112019003408 A2 BR112019003408 A2 BR 112019003408A2 BR 112019003408 A BR112019003408 A BR 112019003408A BR 112019003408 A BR112019003408 A BR 112019003408A BR 112019003408 A2 BR112019003408 A2 BR 112019003408A2
- Authority
- BR
- Brazil
- Prior art keywords
- melk
- monoclonal antibody
- antibody against
- present
- against melk
- Prior art date
Links
- 101150054634 melk gene Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 5
- DKZYXHCYPUVGAF-UHFFFAOYSA-N 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone Chemical compound CN(C)CC1CCC(CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O DKZYXHCYPUVGAF-UHFFFAOYSA-N 0.000 abstract 2
- 229940124787 MELK inhibitor Drugs 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
a presente invenção refere-se a um anticorpo monoclonal contra a melk. além disso, a presente invenção proporciona um método para diagnosticar uma doença relacionada à melk, um método para detectar uma proteína melk, um método para avaliar um efeito do fármaco após um tratamento com um inibidor da melk e um método para o exame de um indivíduo para quem um tratamento com um inibidor da melk é altamente eficaz, cada método compreendendo o uso do anticorpo monoclonal, e um reagente de diagnóstico contendo o anticorpo supracitado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016169085 | 2016-08-31 | ||
PCT/JP2017/030443 WO2018043311A1 (ja) | 2016-08-31 | 2017-08-25 | Melkに対するモノクローナル抗体およびその使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019003408A2 true BR112019003408A2 (pt) | 2019-06-25 |
Family
ID=61301839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019003408A BR112019003408A2 (pt) | 2016-08-31 | 2017-08-25 | anticorpo monoclonal contra a melk e utilização da mesma |
Country Status (14)
Country | Link |
---|---|
US (1) | US11066477B2 (pt) |
EP (1) | EP3508576A4 (pt) |
JP (1) | JP7094557B2 (pt) |
KR (1) | KR102579047B1 (pt) |
CN (1) | CN109890963B (pt) |
AU (1) | AU2017318907B2 (pt) |
BR (1) | BR112019003408A2 (pt) |
CA (1) | CA3035160A1 (pt) |
IL (1) | IL264826B1 (pt) |
MX (1) | MX2019002269A (pt) |
RU (1) | RU2756982C2 (pt) |
SG (2) | SG10202100683RA (pt) |
TW (1) | TWI780067B (pt) |
WO (1) | WO2018043311A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114174339A (zh) * | 2019-06-07 | 2022-03-11 | 阿迪马布有限责任公司 | 高亲和力抗cd3抗体及其产生和使用方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
JP5087059B2 (ja) | 2001-10-31 | 2012-11-28 | 杏林製薬株式会社 | 4−(2−メチル−1−イミダゾリル)−2,2−ジフェニルブタンアミドの製造方法 |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
EP1651956A4 (en) | 2003-08-14 | 2008-08-20 | Exelixis Inc | MELKS AS MODIFIERS OF THE ACTION ACTION MECHANISM AND METHODS OF USE |
JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
JP5028601B2 (ja) | 2004-08-10 | 2012-09-19 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
CA2629473A1 (en) * | 2005-11-10 | 2007-05-24 | Exelixis, Inc. | Kifs as modifiers of the rho pathway and methods of use |
WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
US9075066B2 (en) * | 2008-04-21 | 2015-07-07 | Korea Research Institute Of Bioscience And Biotechnology | CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer |
TWI466680B (zh) | 2008-08-01 | 2015-01-01 | Oncotherapy Science Inc | Melk抗原決定位胜肽及含此胜肽的疫苗 |
TWI485245B (zh) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之melk胜肽及含此胜肽之疫苗 |
SG10201505951VA (en) | 2010-07-30 | 2015-08-28 | Oncotherapy Science Inc | Quinoline derivatives and melk inhibitors containing the same |
EP2574929A1 (en) * | 2011-09-28 | 2013-04-03 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker in diagnosing prostate cancer (PC) |
JP6159948B2 (ja) | 2012-01-19 | 2017-07-12 | オンコセラピー・サイエンス株式会社 | 1,5−ナフチリジン誘導体および該誘導体を含むmelk阻害剤 |
RU2504785C1 (ru) * | 2012-11-23 | 2014-01-20 | Общество с ограниченной ответственностью "Синтавр" | Способ диагностики рака молочной железы |
ES2669450T3 (es) * | 2013-01-11 | 2018-05-25 | Novartis Ag | Regulación de MELK para el tratamiento de cáncer de mama |
WO2016092865A1 (ja) * | 2014-12-12 | 2016-06-16 | 国立大学法人京都大学 | アミロイドβの22位及び23位のターン構造を極めて特異的に認識する抗体 |
-
2017
- 2017-08-25 CA CA3035160A patent/CA3035160A1/en active Pending
- 2017-08-25 JP JP2018537214A patent/JP7094557B2/ja active Active
- 2017-08-25 IL IL264826A patent/IL264826B1/en unknown
- 2017-08-25 WO PCT/JP2017/030443 patent/WO2018043311A1/ja unknown
- 2017-08-25 SG SG10202100683RA patent/SG10202100683RA/en unknown
- 2017-08-25 MX MX2019002269A patent/MX2019002269A/es unknown
- 2017-08-25 RU RU2019107355A patent/RU2756982C2/ru active
- 2017-08-25 CN CN201780067183.0A patent/CN109890963B/zh active Active
- 2017-08-25 US US16/328,259 patent/US11066477B2/en active Active
- 2017-08-25 AU AU2017318907A patent/AU2017318907B2/en active Active
- 2017-08-25 EP EP17846316.2A patent/EP3508576A4/en active Pending
- 2017-08-25 SG SG11201901435UA patent/SG11201901435UA/en unknown
- 2017-08-25 BR BR112019003408A patent/BR112019003408A2/pt unknown
- 2017-08-25 KR KR1020197009204A patent/KR102579047B1/ko active IP Right Grant
- 2017-08-28 TW TW106129146A patent/TWI780067B/zh active
Also Published As
Publication number | Publication date |
---|---|
KR20190043591A (ko) | 2019-04-26 |
JP7094557B2 (ja) | 2022-07-04 |
US20190185575A1 (en) | 2019-06-20 |
IL264826A (pt) | 2019-04-30 |
KR102579047B1 (ko) | 2023-09-14 |
AU2017318907A1 (en) | 2019-03-21 |
RU2019107355A (ru) | 2020-10-01 |
CN109890963A (zh) | 2019-06-14 |
SG11201901435UA (en) | 2019-03-28 |
US11066477B2 (en) | 2021-07-20 |
IL264826B1 (en) | 2024-02-01 |
AU2017318907B2 (en) | 2023-07-06 |
CN109890963B (zh) | 2023-10-03 |
SG10202100683RA (en) | 2021-03-30 |
EP3508576A4 (en) | 2020-04-22 |
MX2019002269A (es) | 2019-09-18 |
TW201818972A (zh) | 2018-06-01 |
CA3035160A1 (en) | 2018-03-08 |
RU2756982C2 (ru) | 2021-10-07 |
WO2018043311A1 (ja) | 2018-03-08 |
TWI780067B (zh) | 2022-10-11 |
RU2019107355A3 (pt) | 2020-11-02 |
EP3508576A1 (en) | 2019-07-10 |
JPWO2018043311A1 (ja) | 2019-06-24 |
AU2017318907A2 (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017025297A2 (pt) | anticorpos anti-gitr para diagnóstico do câncer | |
BR112018071583A2 (pt) | métodos para determinar dpp3 e métodos terapêuticos | |
BR112017017076A2 (pt) | inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre. | |
BR112017010414A2 (pt) | métodos e composições para radiomarcação com 18f de substâncias biológicas | |
ECSP10010322A (es) | Anticuerpos contra el virus de la influenza y métodos de uso de los mismos | |
BR112017004141B8 (pt) | Agente de imagemamento e seu uso | |
CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
BR112018000749A2 (pt) | métodos e composições para a diagnose e para o tratamento de adrenoleucodistrofia | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
MX2020000186A (es) | Ensayos para evaluar los niveles de anticuerpos neutralizantes en sujetos tratados con un fármaco biológico y usos de los mismos en medicina personalizada. | |
BR112019003951A2 (pt) | métodos e composição para a predição da atividade de enzastaurina | |
BR112017004136A2 (pt) | sondas para imageamento de proteína de huntingtina | |
BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
BR112017004140A2 (pt) | sondas para imageamento de proteína de huntingtina | |
BR112017025995A2 (pt) | inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal | |
CO2019002607A2 (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto | |
AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
CL2022000030A1 (es) | Moléculas de unión a claudina-6 y usos de las mismas | |
BR112017004883A2 (pt) | ensaio de diagnóstico baseado em fragmento de rgma | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
BR112019011713A2 (pt) | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma | |
MX2016009490A (es) | Ensayo novedoso para detectar periostina humana. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |